Lab
Synergene Laboratory LLC
Synergene Laboratory LLC was paid $63K by Medicaid between Mar 2019 and Dec 2020, across 48 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 34% of everything it billed.
33Billing provider infoSYNERGENE LABORATORY LLC
HOUSTON, TX 77092
HOUSTON, TX 77092
33aNPI1659759520assigned 05/12/2015
33bProvider typeClinical Medical Laboratory
28Total paid$63K
24GClaims25,510
24DCodes billed48
24AFirst – last monthMar 2019 – Dec 2020
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#169 of 436
Median peer was paid$17K
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 6,400 | $799.33 | |
| 2020 | 19,110 | $62K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 34% | 4,382 | 227 | $22K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 21% | 850 | 693 | $13K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 19% | 922 | 224 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.1% | 317 | 314 | $3K |
| 87640 | 3.6% | 387 | 223 | $2K | |
| 87641 | 3.3% | 369 | 103 | $2K | |
| 87653 | 2.5% | 380 | 223 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.5% | 380 | 223 | $2K |
| 87481 | 2.4% | 385 | 223 | $2K | |
| 87500 | 2.1% | 206 | 103 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 61 | 51 | $750.22 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 268 | 249 | $278.34 |
36 more codes
| 80061 | Lipid panel | <1% | 703 | $278.26 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,137 | $267.34 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 845 | $225.43 |
| 80053 | Comprehensive metabolic panel | <1% | 1,361 | $220.45 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 856 | $200.15 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 41 | $157.20 |
| 84439 | <1% | 304 | $144.89 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,308 | $137.39 |
| 82607 | <1% | 144 | $102.34 | |
| 86141 | <1% | 27 | $98.36 | |
| 84481 | <1% | 54 | $78.05 | |
| 87486 | <1% | 61 | $63.17 | |
| 87581 | <1% | 61 | $63.17 | |
| 86376 | <1% | 32 | $47.38 | |
| 82746 | <1% | 45 | $33.83 | |
| 84403 | <1% | 12 | $24.09 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 767 | $21.00 |
| 82728 | <1% | 41 | $18.64 | |
| 80164 | <1% | 63 | $18.31 | |
| 87186 | <1% | 480 | $15.00 | |
| 87077 | <1% | 489 | $14.00 | |
| 81001 | <1% | 790 | $8.22 | |
| 83550 | <1% | 13 | $8.16 | |
| 84134 | <1% | 199 | $6.32 | |
| 82140 | <1% | 52 | $6.31 | |
| 83735 | <1% | 133 | $5.80 | |
| 83540 | <1% | 27 | $2.80 | |
| 85610 | 0% | 86 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 40 | $0.00 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 58 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 181 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 1,744 | $0.00 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 1,344 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 16 | $0.00 |
| 83880 | 0% | 16 | $0.00 | |
| 87088 | 0% | 73 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWERNER, BLAKE (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Heartland Health Laboratories, LLC | Lenexa, KS | $1.10M |
| Telezoe, LLC | Addison, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.